Celebrating a New Era in Type 1 Diabetes Research - A Message from TrialNet Chair Kevan C. Herold, MD
TrialNet Chair Kevan C. Herold, MD, Yale University, reflects on key accomplishments of the past year and shares direction for 2024 and beyond.
Dear TrialNet family,
As we start the new year, I want to take time to recognize TrialNet’s major achievements in 2023 and share our direction for advancing type 1 diabetes (T1D) research in the year ahead.